Ondansetron Accord

Ondansetron, the active ingredient in Ondansetron Accord, is a 5-HT3 receptor antagonist presented as a strength/form for oral use. It treats nausea and vomiting associated with chemotherapy, radiation therapy, and surgery in adult and pediatric patients. GNH USA supplies Ondansetron Accord as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

GNH USA supplies Ondansetron Accord as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Ondansetron Accord is a selective 5‑HT3 receptor antagonist that is used to prevent ​        ​  ​  ​  ​  ​  ​  ​  ​  ​  ​      ​  ​  ​  ​ ​  ​  ​  ​    ​  ​  ​    ​             ​                 …    …  …  …  …

- Chemotherapy‑induced nausea and vomiting: Reduces the frequency  ​  ​    …   …   …   …  … - Post‑operative      …   … ‑           …    …